The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Exelixis Announces August 2nd Webcast of Second Quarter 2012 Financial Results Conference Call

Thursday, July 19, 2012

Exelixis Announces August 2nd Webcast of Second Quarter 2012 Financial Results Conference Call16:15 EDT Thursday, July 19, 2012 SOUTH SAN FRANCISCO, Calif. (Business Wire) -- Exelixis, Inc. (NASDAQ: EXEL) will release its second quarter 2012 financial results on Thursday, August 2, 2012, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com. An archived replay of the webcast will be available on the Event Calendar page under Investors at http://www.exelixis.com and via phone until 11:59 p.m. PDT on September 2, 2012. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 13635336. About Exelixis Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at http://www.exelixis.com. Exelixis, Inc.Charles Butler, 650-837-7277Vice President,Investor Relations andCorporate Communicationscbutler@exelixis.com